The bioregulatory preparation Prostatilen is generally applied across domains where additional symptomatic support is needed in urological health, particularly for conditions linked to organ-specific functional stress. The use of this preparation is generally associated with conditions involving inflammatory processes and chronic prostate disorders. The preparation is relevant for supportive management during periods of functional strain, focusing on maintaining urological health during these times.

Symptom Relief and Patient Benefit

This preparation is commonly used to help with symptoms related to inflammatory or irritative states such as chronic pelvic pain and discomfort, and symptom clusters that interfere with daily functioning, particularly those related to the lower urinary tract. This includes easing the frequency of urination, difficulty with voiding, and bothersome nocturia. The medication may also be part of symptomatic management for issues related to spermatogenesis and impairments of sexual performance secondary to prostate pathology.

Quick Fact: Relief for Pain and Urination
The preparation may assist with easing the overall symptom burden by supporting management of pelvic pain and contributing to the maintenance of comfortable, stable voiding patterns.

Population Eligibility and Contraindications

The eligibility for Prostatilen is strictly defined by its intended use as a prostate-specific agent and a clear list of regulatory exclusions.

Category	Eligibility Status (Official Regulatory View)
Populations Allowed	Adult Males only. The medicine is indicated solely for male-specific urological conditions related to the prostate gland, which restricts its labeled use to adult men (18+).
Populations Contraindicated	Known Hypersensitivity to the active substance (Prostate Extract), excipients, or cattle proteins (due to the drug's biological origin).
Condition Contraindications	Use is formally prohibited (contraindicated) for patients with diagnosed renal failure and those with a history of myocardial infarction (as stated in official regulatory summaries for certain formulations).
Age/Gender Status	Females (including Pregnancy/Lactation): Ineligible by indication; use is not documented or recommended. Pediatric Use: Not indicated or recommended, as the conditions treated do not apply to this age group.

Eligibility-Related Restrictions

Use requires caution and consultation if the patient presents with severe kidney, liver, or gastrointestinal conditions, or during an acute urinary tract infection, as specified in the official prescribing information. These restrictions ensure the medicine is only used within officially established safety parameters.

Interactions with other medicines and products

The official interaction profile for Prostatilen (Prostate Extract, a Bioregulatory Peptide Preparation) is defined by the information available in major government regulatory sources. An extensive review of official prescribing information has confirmed that specific interaction mechanisms, warnings, and restrictions are not formally documented in the standardized regulatory format (e.g., FDA or EMA labels).

---

Official Regulatory Status of Interactions

The interaction structure for this preparation is characterized by the absence of specific warnings across formal regulatory categories, as detailed below.

Category	Regulatory Status
Specific Interacting Medicines	None formally listed.
Metabolic Mechanisms (CYP)	No specific pharmacokinetic interaction mechanisms are formally documented.
Timing-Based Rules	No mandatory timing separation requirements are documented.
Food, Alcohol, Supplements	No specific interactions with food, alcohol, or herbal products are formally documented.

---

Conclusion on Regulatory Constraints

Publicly available government documentation currently does not identify any specific restrictions or management requirements related to co-administration. No formal regulatory statements establish mandatory constraints on using Prostatilen alongside other medicinal products or substances, nor are there any designated contraindicated combinations or population-specific interaction cautions noted in the official prescribing information.

How Prostatilen Works at a Biological Level

Prostatilen's active peptide components act primarily on prostate gland tissue cells, leukocytes, and local microvasculature. The mechanism involves membrane stabilization and anti-inflammatory modulation by reducing damaging lipid peroxidation and influencing the infiltration and activity of white blood cells in the prostatic tissue. This action modulates the inflammatory cascade, influencing the processes that contribute to localized tissue fluid accumulation.

Simultaneously, the drug's components influence local hemostasis by affecting platelet aggregation and the permeability of capillary walls. This modifies local blood flow dynamics by influencing vascular congestion and stasis, which contributes to tissue nourishment (trophism) and metabolite clearance. Further, Prostatilen acts as a trophic agent that influences the internal cellular environment by affecting enzyme activity and energy production, thereby modulating the gland's physiological function and secretory processes.

Prostatilen, a polypeptide preparation, is utilized according to highly structured, cyclic regimens defined in regulatory-equivalent documentation. Its usage is standardized across two distinct routes of administration: intramuscular injection (via a solution) and rectal insertion (via suppositories).

Administration Routes and Standard Dosing

The standard adult dosing pattern requires administration once daily for both dosage forms. For the intramuscular solution, the standard dose is generally in the range of 5 mg to 10 mg of the preparation. The rectal form typically uses a single suppository, often standardized at a strength of 0.03 g (30 mg) of Prostate Extract.

Course Duration and Cyclic Use

A key procedural constraint defining the medicine's use is its cyclic nature. Both dosage forms are intended for short, dedicated periods of administration rather than continuous therapy. A typical injection course is finite, lasting between 5 and 10 days. The course for suppositories is generally 10 to 15 days.

Following a completed course, the official use protocol specifies that the treatment may be repeated intermittently. Documented regimens demonstrate subsequent courses being initiated after an interval, such as every one to three months. No specific instructions regarding timing relative to meals, preparation requirements, or dosage adjustments for specific populations are uniformly provided in official usage guidelines.

Research evidence / Overview of Studies for Prostatilen

The research base for Prostatilen, a preparation based on prostate peptides, is primarily comprised of clinical studies that have examined the product in several contexts affecting the male genitourinary system. The following overview is based on findings reported in peer-reviewed literature and regulatory summaries, focusing only on the structure of the evidence and acknowledged limitations.

---

Evidence for Use in Chronic Prostatitis and CPPS

Research explored whether the preparation was associated with changes in men diagnosed with chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS). Studies were applied in research contexts involving fluctuating or unstable symptoms, focusing on outcomes related to physical discomfort and daily functioning.

What Researchers Studied and Reported: Researchers monitored changes in core symptoms (e.g., pain, urinary issues) using standardized tools like the NIH-CPSI. Studies also monitored outcomes linked to inflammatory states. Studies observed patterns in these symptom scores and markers, but findings were mixed and varied across different study cohorts.

What Remains Uncertain: Evidence is limited, particularly as many studies involved small patient populations. The follow-up durations were limited, often extending only a few weeks to a few months. Therefore, there is limited information for long-term outcomes and the durability of the observed patterns.

---

Evidence for Use in Male Reproductive Health

Research examined the preparation in contexts related to impaired spermatogenesis associated with chronic prostate issues. These studies, often Phase III clinical trials, explored outcomes reflecting functional imbalance.

What Researchers Studied and Reported: The primary outcomes evaluated were surrogate markers of reproductive function, specifically sperm parameters (concentration, motility). Findings described patterns in these markers, but comparative data showed variability against control preparations.

What Remains Uncertain: A key limitation is that the studies focused on surrogate markers (measures of sperm quality), while long-term clinical outcomes, such as pregnancy rates, were not evaluated. Furthermore, the duration of active treatment and follow-up was very short-term, generally spanning only 10 to 16 days of therapy, offering limited insight into long-term changes.

Common questions about Prostatilen (FAQ)

---

Q: What is Prostatilen used for?

Prostatilen is indicated for use in adult males to support certain conditions related to the prostate gland, such as chronic prostatitis. The specific uses are outlined in the product labeling.

---

Q: How should I take Prostatilen?

The administration (such as dosage, frequency, and duration of use) for Prostatilen is determined by a healthcare professional. Patients should carefully follow the prescribed instructions and the information provided in the product leaflet.

---

Q: Is Prostatilen safe?

Like all medicinal products, Prostatilen may have side effects. The decision regarding its suitability should be made by a doctor who can assess the potential risks and benefits based on an individual's specific health profile. The product label lists known safety information.

---

Q: Can Prostatilen interact with other medications?

There is limited data available regarding drug interactions with Prostatilen. It is recommended that patients inform their doctor about all prescription drugs, over-the-counter medicines, and supplements currently being taken to avoid potential interactions.

Official Storage and Disposal Instructions

Regulatory documentation defines specific, mandatory conditions for storing and disposing of Prostatilen to maintain its stability.

Storage Requirements

Storage Factor	Official Requirement
Temperature	Store at a temperature not exceeding 25 C (77 F).
Protection	Keep the product in its original package, stored in a dry place, and protect from light and heat.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused Prostatilen must be managed according to regulated procedures. Do not throw away medicines via wastewater or household waste to help protect the environment. Instructions mandate consulting a pharmacist regarding the proper method for discarding unused products according to local regulatory requirements.